In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Medical Services Patients & Visitors Health Library For Medical Professionals Quality About Us PhysicianLink
Text Size:  -   +  |  Print Page  |  Email Page

Pulmonary Research



Research is one of the components that make us unique at Baptist Health Lexington.  Our highly trained staff is dedicated to providing the latest innovations and newest therapies in a community-based setting.  Baptist Health Lexington is working to improve the lives of our patients with pulmonary disease.

Below is a listing of current pulmonary clinical trials:

 

IRB 1179—PIPF-031 EAP

Title: A Treatment Protocol to Allow Patients in the US with Idiopathic Pulmonary Fibrosis Access to Pirfenidone

Sponsored by: InterMune, Inc

Status:Enrolling

 

Purpose:  To provide access to pirfenidone to patients in the US with idiopathic pulmonary fibrosis (IPF)

 

Main Eligibility:  Clinical and radiographic diagnosis of IPF including the presence of interstitial pneumonia (UIP) pattern or possible UIP on historical HRCT (ATS 2011); and % FVC>50 and %DLco > 30%

 

For additional information, please contact Ruthie Hoefner RNC-OB, MSN, at 859-260-4527 or Karen Willis RN, CCRC at 859.260.6440

 

 

IRB 1155—1199.187 IPF study

Title: A double blind randomized placebo controlled trial evaluating the effect of oral nintedanib 150 mg twice daily on high resolution computerized tomography quantitative lung fibrosis score, lung function, six minute walk test distance and St. George’s Respiratory Questionnaire after twelve months of treatment in patients with Idiopathic Pulmonary Fibrosis with continued evaluations over a period of up to eighteen months

Sponsored by:Boehringer Ingelheim Pharmaceuticals, Inc

Status: closed to enrollment, patients continue in follow-up

 

Purpose: See title

 

Main Eligibility: Confirmed diagnosis of IPF according to 2011 ATS/ERS/JRS/ ALAT guideline by HRCT or lung biopsy taken within 24 months prior to providing Informed Consent; Forced Vital Capacity (FVC) >50% of predicted; Carbon monoxide Diffusion Capacity (DLCO) (corrected for hemoglobin 30-79% of predicted)

 

For additional information, please contact Karen Willis RN, CCRC at 859-260-6440 or Ruthie Hoefner RNC-OB, MSN, at 859.260.4527

 

 

IRB 1037—1199.033 Extended IPF

Title:  An open-label extension trial of the long term safety of oral BIBF 1120 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Sponsored by:Boehringer Ingelheim Pharmaceuticals, Inc

Status:Closed to Enrollment, patients in follow-up

 

Purpose: To assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis

 

Main Eligibility: Completion of one year treatment and follow-up period in the 1199.34 IPF trial

 

For additional information, please contact Karen Willis RN, CCRC at 859-260-6440 or Ruthie Hoefner RNC-OB, MSN, at 859.260.4527